FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070995476> ?p ?o ?g. }

• W2070995476 endingPage "628" @default.
• W2070995476 startingPage "621" @default.
• W2070995476 abstract "L’atomoxétine (Strattera®) est un médicament non stimulant ayant reçu une autorisation de mise sur le marché dans plusieurs pays, dans l’indication du trouble déficit de l’attention/hyperactivité (TDAH), chez l’enfant de 6 ans et plus et chez l’adolescent. C’est un inhibiteur sélectif de la recapture de la noradrénaline ; sa posologie recommandée est de 1,2 mg/kg/jour par voie orale, en une ou deux prises. L’efficacité de l’atomoxétine sur les symptômes de TDAH a été démontrée au cours de six essais cliniques randomisés en double aveugle versus placebo, par l’amélioration du score de l’échelle de symptômes ADHD-RS (ADHD rating scale) et par celle des scores d’autres échelles d’évaluation (CGI, Conners parents/enseignant). L’efficacité s’est maintenue jusqu’au lendemain matin, lors d’une administration en une prise par jour le matin. L’atomoxétine a permis également une amélioration de la qualité de vie de l’enfant dans ses dimensions psychosociale, comportementale et d’estime de soi. De plus, une étude de prévention des rechutes, randomisée en double aveugle versus placebo chez des enfants et adolescents initialement répondeurs à l’atomoxétine pendant 10 semaines, a démontré le maintien d’efficacité de l’atomoxétine à long terme. Le profil de tolérance de l’atomoxétine a été analysé avec un recul de plus de deux ans d’exposition au traitement pour certains patients. Les effets secondaires les plus fréquents sont des troubles digestifs et une baisse de l’appétit, le plus souvent transitoires, n’entraînant pas de retentissement significatif sur l’évolution staturo-pondérale des enfants traités. Au total, l’atomoxétine représente une modalité thérapeutique médicamenteuse nouvelle et intéressante dans le traitement du TDAH de l’enfant et de l’adolescent, en association à une prise en charge multimodale du trouble. Atomoxetine (Strattera®) is the first non-stimulant drug to be approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children6 years of age and adolescents. Atomoxetine is a highly specific inhibitor of the presynaptic norepinephrine transporter, with minimal affinity for other transporters or other neurotransmitter receptors. The target dose is 1.2 mg/kg, in a once- or twice-daily oral administration. Six randomized, double blind, placebo-controlled clinical trials have demonstrated that atomoxetine was more effective than placebo for the treatment of children and adolescents with ADHD. All these trials have shown a consistent improvement in the ADHD rating scale (ADHD-RS) from baseline in the patients treated with atomoxetine, compared with that of the placebo group. The improvement of ADHD symptoms was confirmed by the other secondary efficacy measures (the Clinical Global Impression, CGI, the Conners ADHD rating scale/parent, teacher). The duration of action of atomoxetine on ADHD symptoms extended throughout the waking hours, and the drug effects persisted up to the next morning with a single morning dose. Significant improvements were also observed with atomoxetine compared to placebo, in several aspects of the quality of life measurement (social and family functioning), and the child's self-esteem. In addition, in patients who responded favourably to initial treatment, atomoxetine was shown to be superior to placebo in maintaining a long term-response, up to 18 months. Atomoxetine was effective and safe, both in young children and adolescents with ADHD. Preliminary data also support the potential efficacy of atomoxetine in managing patients with ADHD and comorbid conditions, such as tic disorders, oppositional-defiant and conduct disorders. As of June 2004, over 3 000 children and adolescents have been enrolled in clinical trials of atomoxetine, with about 1 200 of them treated for more than 1 year and about 400 of them treated for more than 2 years. Atomoxetine was well tolerated in most individuals, the two more common adverse events reported were gastro-intestinal disorders and decreased appetite. These side effects were generally noted to be transient. No significant changes in weight and height gain was reported over the long-term follow-up. There was no evidence of symptoms rebound and no evidence of an acute discontinuation syndrome when discontinuing treatment. In addition, given the mechanism of action of atomoxetine in the central nervous system, and lack of subjective, physiological and psychomotor effects reported in experimental conditions, it is unlikely that atomoxetine would have abuse potential. Results from clinical trials demonstrated that atomoxetine is effective and well tolerated for the acute and long-term treatment of children and adolescents suffering from ADHD. Atomoxetine should be considered as a new interesting pharmacological option in the treatment of ADHD in association with non pharmacological therapeutic interventions." @default.
• W2070995476 created "2016-06-24" @default.
• W2070995476 creator A5076432030 @default.
• W2070995476 creator A5076456427 @default.
• W2070995476 creator A5083216357 @default.
• W2070995476 date "2007-09-01" @default.
• W2070995476 modified "2023-09-25" @default.
• W2070995476 title "L’atomoxétine (Strattera®), une alternative thérapeutique dans le trouble déficit de l’attention/hyperactivité de l’enfant (TDAH)" @default.
• W2070995476 cites W1514128735 @default.
• W2070995476 cites W1963735974 @default.
• W2070995476 cites W1965946834 @default.
• W2070995476 cites W1970212093 @default.
• W2070995476 cites W1973987518 @default.
• W2070995476 cites W1980333466 @default.
• W2070995476 cites W1993327116 @default.
• W2070995476 cites W1993945668 @default.
• W2070995476 cites W2001108200 @default.
• W2070995476 cites W2016483680 @default.
• W2070995476 cites W2033447811 @default.
• W2070995476 cites W2040513075 @default.
• W2070995476 cites W2056434954 @default.
• W2070995476 cites W2057760214 @default.
• W2070995476 cites W2083338868 @default.
• W2070995476 cites W2094270069 @default.
• W2070995476 cites W2112484680 @default.
• W2070995476 cites W2122518346 @default.
• W2070995476 cites W2123980944 @default.
• W2070995476 cites W2128074636 @default.
• W2070995476 cites W629283852 @default.
• W2070995476 cites W73658022 @default.
• W2070995476 cites W2066201328 @default.
• W2070995476 cites W2489419499 @default.
• W2070995476 doi "https://doi.org/10.1016/s0013-7006(07)92063-1" @default.
• W2070995476 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18033153" @default.
• W2070995476 hasPublicationYear "2007" @default.
• W2070995476 type Work @default.
• W2070995476 sameAs 2070995476 @default.
• W2070995476 citedByCount "1" @default.
• W2070995476 crossrefType "journal-article" @default.
• W2070995476 hasAuthorship W2070995476A5076432030 @default.
• W2070995476 hasAuthorship W2070995476A5076456427 @default.
• W2070995476 hasAuthorship W2070995476A5083216357 @default.
• W2070995476 hasConcept C138885662 @default.
• W2070995476 hasConcept C15708023 @default.
• W2070995476 hasConcept C29456083 @default.
• W2070995476 hasConcept C71924100 @default.
• W2070995476 hasConceptScore W2070995476C138885662 @default.
• W2070995476 hasConceptScore W2070995476C15708023 @default.
• W2070995476 hasConceptScore W2070995476C29456083 @default.
• W2070995476 hasConceptScore W2070995476C71924100 @default.
• W2070995476 hasIssue "4" @default.
• W2070995476 hasLocation W20709954761 @default.
• W2070995476 hasLocation W20709954762 @default.
• W2070995476 hasOpenAccess W2070995476 @default.
• W2070995476 hasPrimaryLocation W20709954761 @default.
• W2070995476 hasRelatedWork W2473335724 @default.
• W2070995476 hasRelatedWork W2609344916 @default.
• W2070995476 hasRelatedWork W2748952813 @default.
• W2070995476 hasRelatedWork W2780307509 @default.
• W2070995476 hasRelatedWork W2789448498 @default.
• W2070995476 hasRelatedWork W2899084033 @default.
• W2070995476 hasRelatedWork W4210390885 @default.
• W2070995476 hasRelatedWork W59019880 @default.
• W2070995476 hasRelatedWork W2308060692 @default.
• W2070995476 hasRelatedWork W2478882070 @default.
• W2070995476 hasVolume "33" @default.
• W2070995476 isParatext "false" @default.
• W2070995476 isRetracted "false" @default.
• W2070995476 magId "2070995476" @default.
• W2070995476 workType "article" @default.